Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
A phase 1/2 trial of GTAEXS617 in head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma, non-small-cell lung cancer, ovarian cancer, HR-positive / HER2-negative breast cancer and triple-negative breast cancer, run by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., now recruiting.
Overview
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05985655 by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., with 230 participants planned, started 2023-07-06 and due to reach its primary completion in 2028-01. Interventions recorded: GTAEXS617 and SoC.
Similar pages
not linked directly; found by shared links- TrialA Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Shares Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Shares Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Shares Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TreatmentJK08
Shares Triple-negative breast cancer (TNBC), Head and neck squamous cell carcinoma, Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
Shares Triple-negative breast cancer (TNBC), Ovarian cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.
- TrialStudy of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.